Valopicitabine
Alternative Names: NM 107; NM-283; NMC-283; val-mCydLatest Information Update: 02 Oct 2021
At a glance
- Originator Idenix Pharmaceuticals; University of Cagliari
- Developer Idenix Pharmaceuticals
- Class Antivirals; Nucleosides; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 08 Aug 2007 Discontinued -Phase-I/II clinical trials in Hepatitis C (Treatment-naive) in Puerto Rico (PO) (NCT00120835)
- 08 Aug 2007 Discontinued - Phase-II for Hepatitis C treatment in USA (PO)
- 17 Jul 2007 Suspended - Phase-II for Hepatitis C treatment in USA (PO)